Literature DB >> 10048965

T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma.

J Fagerberg1, Q Yi, D Gigliotti, U Harmenberg, U Rudén, B Persson, A Osterborg, H Mellstedt.   

Abstract

The idiotypic structures of the myeloma protein might be regarded as tumor-specific antigens. The present study was designed to map T-cell epitopes of the idiotypic myeloma protein to prove the existence of naturally occurring major-histocompatibility-complex-dependent idiotype (peptide)-specific T cells in multiple myeloma. The fine specificity of idiotype-reactive, interferon-gamma-producing blood T cells of a patient with multiple myeloma stage I was characterized by identification of idiotype (heavy and light chains)-derived MHC-restricted T-cell epitopes. T cells specifically reacting with peptides corresponding to each of the 3 complementarity-determining regions (CDRs) of the heavy-chain variable part (V(H)) of the autologous idiotype were found. In contrast, none of the peptides corresponding to the 3 CDRs of the light chain (V(L)) induced a specific T-cell response. The idiotype amino-acid sequence corresponding to the junction of the V(H), diversity (D), and joining (J) gene segments of the VH appeared to be an important target for T cells, since the sequence expressed MHC-class-I- as well as MHC-class-II-restricted epitopes. The study provides further support for the existence of MHC-restricted idiotype-specific T cells, which may target immunogenic CDR peptides in multiple myeloma. Such T cells could be an important part of the specific anti-tumor immune responses induced in idiotype vaccination protocols.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10048965     DOI: 10.1002/(sici)1097-0215(19990301)80:5<671::aid-ijc7>3.0.co;2-e

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Deregulated cytokine network and defective Th1 immune response in multiple myeloma.

Authors:  M A Frassanito; A Cusmai; F Dammacco
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

2.  Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.

Authors:  Jinsheng Weng; Soung-Chul Cha; Satoko Matsueda; Gheath Alatrash; Michael S Popescu; Qing Yi; Jeffrey J Molldrem; Michael Wang; Sattva S Neelapu; Larry W Kwak
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

3.  Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

Authors:  Michael Hundemer; Stefanie Schmidt; Maud Condomines; Alaviana Lupu; Dirk Hose; Marion Moos; Friedrich Cremer; Christian Kleist; Peter Terness; Sebastian Belle; Anthony D Ho; Hartmut Goldschmidt; Bernard Klein; Olaf Christensen
Journal:  Exp Hematol       Date:  2006-04       Impact factor: 3.084

4.  MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.

Authors:  Qiang Wang; Dongyu Zhao; Miao Xian; Zhuo Wang; Enguang Bi; Pan Su; Jianfei Qian; Xingzhe Ma; Maojie Yang; Lintao Liu; Youli Zu; Sai Ravi Pingali; Kaifu Chen; Zhen Cai; Qing Yi
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

Review 5.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

6.  Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.

Authors:  Sivasubramanian Baskar; Carol B Kobrin; Larry W Kwak
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

7.  Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.

Authors:  Sebastian Belle; Fang Han; Maud Condomines; Olaf Christensen; Mathias Witzens-Harig; Bernd Kasper; Christian Kleist; Peter Terness; Marion Moos; Friedrich Cremer; Dirk Hose; Anthony D Ho; Hartmut Goldschmidt; Bernard Klein; Michael Hundemer
Journal:  Eur J Haematol       Date:  2008-03-19       Impact factor: 2.997

Review 8.  The effect of age on the B-cell repertoire.

Authors:  M E Weksler; P Szabo
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.542

9.  CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability.

Authors:  Xingzhe Ma; Liuling Xiao; Lintao Liu; Lingqun Ye; Pan Su; Enguang Bi; Qiang Wang; Maojie Yang; Jianfei Qian; Qing Yi
Journal:  Cell Metab       Date:  2021-03-09       Impact factor: 27.287

10.  Lymphomas can develop from B cells chronically helped by idiotype-specific T cells.

Authors:  Michael M Zangani; Marianne Frøyland; Gao Yue Qiu; Leonardo A Meza-Zepeda; Jeffery L Kutok; Keith M Thompson; Ludvig A Munthe; Bjarne Bogen
Journal:  J Exp Med       Date:  2007-05-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.